BRP, a naturally occurring 12-amino-acid peptide found by Stanford researchers using AI, cut food intake by up to 50% in mice and minipigs and drove fat-focused weight loss in obese mice.
Peptide Predictor scanned 20,000 human protein-coding genes, narrowed candidates to 373 prohormones and 2,683 possible peptides, then flagged BRP as a strong neuronal activator distinct from GLP-1 pathways.
Fourteen days of daily BRP injections left obese mice about 3 grams lighter while control mice gained about 3 grams; treated animals also showed improved glucose and insulin tolerance.
Animal tests showed no clear signs of nausea-related behavior, constipation, major muscle loss or changes in movement and water intake, suggesting a more targeted hypothalamus-based mechanism than semaglutide.
The Nature study remains preclinical, and the team is still identifying BRP's receptor and trying to extend its short-lived effects before planned human clinical trials.
How did an AI tool uncover a hidden human hormone that might revolutionize precision weight loss therapies forever?
Could a newly discovered brain-targeting peptide finally dethrone Ozempic by melting fat without the dreaded nausea or muscle loss?
BRP and the Future of Weight Loss: Inside the 2026 Stanford Breakthrough and the Race Beyond GLP-1 Drugs
Overview
In July 2026, Stanford researchers used an AI tool called Peptide Predictor to scan thousands of human genes and discovered BRP, a natural peptide that powerfully reduces appetite by acting specifically in the brain’s hypothalamus. In animal studies, BRP led to rapid and significant weight loss without the side effects seen in current drugs like semaglutide. However, BRP’s exact receptor is still unknown, and its small size means it breaks down quickly in the body, so scientists are working to improve its stability. As BRP moves toward human trials, experts highlight both its promise and the challenges of translating animal results to safe, effective treatments for people.